U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Status:
US Previously Marketed
First approved in 1949

Class (Stereo):
CHEMICAL (ABSOLUTE)



Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)

Dimethyltubocurarine (metocurine) is a non-depolarizing muscle relaxant. It binds to muscle acetylcholine receptor by bridging the to alpha and non-alpha subunits from the ligand binding site. Dimethyltubocurarine was used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.
Status:
US Previously Marketed
First approved in 1949

Class (Stereo):
CHEMICAL (ABSOLUTE)



Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.